Private startup
NewLimit
Not publicly tradedNewLimit develops epigenetic reprogramming medicines intended to restore youthful function to aged cells, starting with liver cells. It was co-founded by Brian…
Most advanced: PreclinicalVerified Sep 2026
Liver disease
DeepTech + MedTechMixed / overview
Organoids and Lab-Grown Models: Could They Improve How We Test Treatments?
Organoids and organ-on-a-chip systems let researchers test drugs on human tissue models before people. The early evidence is promising but specific, and the models still miss much of real human biology.
Explainer6 min read